Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon Long-Term Safety Extension in Alzheimer's Disease
NCT00939783Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Aug 2010
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
A Phase 3 trial of latrepirdine in Alzheimer's disease (AD), sponsored by Pfizer. Started Sep 2009; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00939783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939783.